EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Methotrexate toxicity and intolerance in paediatric inflammatory bowel disease: A retrospective cohort study

Eva Vermeer iD, Eveline L Soetens, Eduard A Struys, Johan E van Limbergen, Maja Bulatović-Ćalasan, Robert de Jonge, Nanne K H de Boer, Tim G J de Meij

Journal of Pediatric Gastroenterology and Nutrition · 2026-02 · 82 (2) · 477-486

DOI: 10.1002/jpn3.70300 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 29.11.2025. Verfasst von Eva Vermeer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Gastroenterology, Emma Children's Hospital, Amsterdam University Medical Centre, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Methotrexate, Inflammatory Bowel Diseases, Chemical and Drug Induced Liver Injury, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Methotrexate (MTX) is frequently prescribed in paediatric inflammatory bowel disease (IBD), with routine laboratory monitoring to detect adverse events (AEs), such as hepatotoxicity and myelotoxicity. However, data on the incidence and predictors of these AEs remain limited. This study aimed to assess the incidence of MTX‐induced AEs in paediatric IBD, and to identify associated factors.

Methods

We conducted a retrospective monocentre cohort study, including paediatric IBD patients initiating MTX at Amsterdam University Medical Centre between 2010 and 2023. We collected demographic, disease and therapy data, and laboratory results. We evaluated biochemical toxicity (hepatotoxicity or myelotoxicity) and nausea and vomiting, classifying AE severity using common terminology criteria for AEs.

Results

A total of 207 paediatric IBD patients (181 Crohn's disease, 17 ulcerative colitis, 9 IBD‐unclassified) starting MTX therapy were included, 114 of whom used MTX as immunomodulator alongside a biological drug. Hepatotoxicity occurred in 41% (61% grade 1, 12% grade 3), and myelotoxicity in 21% (81% mild, 0 severe cases). Nausea was reported in 46%. MTX was discontinued due to an AE in 60 cases (38%), including 27 following hepatotoxicity, 4 following myelotoxicity, and 27 following nausea. Male sex (relative risk [RR] 1.4, p = 0.003) and lower MTX dose (RR 0.9, p = 0.003) predicted biochemical toxicity. Nausea was associated with male sex (RR 1.7, p = 0.002), oral administration (RR 0.5 for subcutaneous route, p < 0.001), and higher MTX dose (RR 1.1, p = 0.005).

Conclusions

MTX‐induced AEs are common but rarely severe in paediatric IBD. Male sex, MTX dosage, and oral administration significantly influence the risk of MTX‐induced AEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateInflammatory Bowel DiseasesChemical and Drug Induced Liver InjuryImmunosuppressive AgentsHumansRetrospective StudiesMaleFemaleChildAdolescentChild, PreschoolIncidenceNausea

Stichwörter der Autor:innen

Crohn's diseaseadverse eventshepatotoxicitymyelotoxicityulcerative colitis

Substanzen

MethotrexateImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Paediatric Gastroenterology, Emma Children's Hospital, Amsterdam University Medical Centre, Amsterdam, the Netherlands.
  • Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam University Medical Centre, Amsterdam, the Netherlands.
  • Amsterdam Reproduction & Development (AR&D) Research Institute, Amsterdam University Medical Centre, Amsterdam, the Netherlands.
  • Department of Laboratory Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands.
  • Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Amsterdam, the Netherlands.

ORCID-Profile: Eva Vermeer

Förderung

  • None

Zitieren

APA

Vermeer, E., Soetens, E. L., Struys, E. A., van Limbergen, J. E., Bulatović-Ćalasan, M., de Jonge, R., de Boer, N. K. H., & de Meij, T. G. J. (2026). Methotrexate toxicity and intolerance in paediatric inflammatory bowel disease: A retrospective cohort study. Journal of Pediatric Gastroenterology and Nutrition, 82(2), 477-486. https://doi.org/10.1002/jpn3.70300

Vancouver

Vermeer E, Soetens EL, Struys EA, van Limbergen JE, Bulatović-Ćalasan M, de Jonge R, et al. Methotrexate toxicity and intolerance in paediatric inflammatory bowel disease: A retrospective cohort study. Journal of Pediatric Gastroenterology and Nutrition. 2026;82(2):477-486. doi:10.1002/jpn3.70300

BibTeX
@article{Vermeer2026,
  author = {Vermeer, Eva and Soetens, Eveline L and Struys, Eduard A and van Limbergen, Johan E and Bulatović-Ćalasan, Maja and de Jonge, Robert and de Boer, Nanne K H and de Meij, Tim G J},
  title = {Methotrexate toxicity and intolerance in paediatric inflammatory bowel disease: A retrospective cohort study},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2026},
  volume = {82},
  number = {2},
  pages = {477--486},
  doi = {10.1002/jpn3.70300}
}
Kostenlos starten →